primari
immunodefici
pid
heterogen
group
disord
affect
distinct
compon
immun
system
follow
definit
agammaglobulinemia
bruton
one
first
prototyp
pid
diseas
subject
intens
studi
elucid
etiolog
develop
effect
treatment
sever
new
diseas
novel
mutat
identifi
last
year
number
genet
defin
pid
exce
recent
defin
genet
defect
clinic
present
reveal
pid
present
recurr
infect
also
lymphoprolifer
autoimmun
allergi
malign
lpsrespons
beigelik
anchor
protein
lrba
defici
prototyp
pid
present
broad
spectrum
clinic
phenotyp
mutat
lrba
encod
lrba
link
defect
vesicl
traffick
includ
transendocytosi
turnov
regulatori
cell
treg
decreas
lrba
protein
function
lead
diminish
express
surfac
treg
cell
patient
present
defect
biolog
show
autoantibodymedi
cytopenia
lymphoprolifer
hypogammaglobulinemia
organspecif
autoimmun
lymphocyt
infiltr
nonlymphoid
organ
although
lrba
defici
first
categor
common
variabl
immunodefici
cvid
autoimmun
manifest
inflammatori
bowel
diseas
clinic
spectrum
extend
latest
report
phenotyp
variat
particular
patient
phenotyp
resembl
autoimmun
lymphoprolif
syndrom
alp
includ
autoimmun
cytopenia
lymphoprolifer
without
hypogammaglobulinemia
describ
studi
present
cohort
turkish
lrbadefici
patient
singl
center
illustr
wide
rang
clinic
manifest
differ
therapeut
approach
depend
clinic
statu
patient
seven
individu
five
famili
affect
lrba
defect
followup
ankara
univers
depart
immunolog
assess
retrospect
studi
inform
consent
taken
parent
accord
declar
helsinki
complet
blood
count
immunoglobulin
level
lymphocyt
subset
lymphocyt
activ
respons
genet
aberr
analyz
well
clinic
data
histopatholog
find
biopsi
specimen
two
patient
underw
hematopoiet
stem
cell
transplant
hsct
posttranspl
followup
data
regard
immunophenotyp
chimer
analysi
evalu
separ
genet
analys
patient
defin
previous
patient
analyz
ngsbase
gene
panel
screen
confirm
sanger
sequenc
describ
peripher
blood
mononuclear
cell
pbmc
transform
ebv
b
cell
line
expand
b
cell
harvest
lyse
frackleton
buffer
mm
trishcl
ph
mm
nacl
mm
nappi
mm
naf
triton
supplement
proteas
inhibitor
cocktail
sigmaaldrich
western
blot
protein
load
follow
antibodi
use
antilrba
sigmaaldrich
anticad
cell
signal
technolog
multicolor
high
rang
protein
ladder
thermo
fisher
use
size
marker
pbmc
patient
healthi
donor
includ
shipment
control
stimul
antibodi
clone
clone
thermo
fisher
scientif
h
cell
seed
polyl
lysineco
coverslip
subsequ
fix
pfa
permeabil
triton
antibodi
lrba
sigmaaldrich
bd
bioscienc
use
secondari
stain
perform
life
technolog
nucleu
counterstain
dapi
slide
analyz
lsm
planapochromat
oil
object
five
differ
area
coverslip
screen
dapi
lrba
express
cell
three
repres
imag
taken
patient
femal
patient
first
present
symptom
age
month
clinic
cours
describ
previous
missens
mutat
lrba
gene
identifi
result
protein
loss
patient
diagnos
possibl
lrba
defici
function
analysi
plan
definit
lrba
defici
howev
due
sever
phenotyp
die
age
year
patient
girl
born
nonconsanguin
parent
present
recurr
respiratori
infect
chronic
diarrhea
start
year
age
year
old
develop
immun
thrombocytopen
purpura
itp
autoimmun
hemolyt
anemia
aiha
episod
resist
immunosuppress
therapi
followup
lymphadenopathi
hepatosplenomegali
develop
immun
workup
reveal
lymphopenia
elev
number
doubl
neg
cell
diagnos
autoimmun
lymphoprolif
syndrom
intraven
immunoglobulin
ivig
replac
therapi
initi
togeth
antibiot
prophylaxi
howev
die
result
sever
pneumonia
episod
age
famili
histori
two
deceas
sibl
present
similar
clinic
phenotyp
newborn
brother
patient
present
clinic
neonat
diabet
immun
workup
normal
apart
slight
reduct
immunoglobulin
g
level
toddler
age
unev
followup
apart
two
episod
viral
pneumonia
due
respiratori
syncyti
viru
rsv
adenoviru
howev
age
year
develop
itp
resist
steroid
ivig
plasma
exchang
therapi
follow
epstein
barr
viru
ebv
induc
lymphoprolifer
splenomegali
histopatholog
evalu
lymph
node
biopsi
show
reactiv
lymphocytosi
year
old
noninfecti
chronic
secretori
diarrhea
start
colonoscop
biopsi
reveal
inflammatori
bowel
diseas
ibd
like
mucos
inflamm
prompt
initi
total
parenter
nutrit
tpn
sever
nephrot
rang
proteinuria
underw
renal
biopsi
lymphocyt
infiltr
renal
cortex
observ
diseas
cours
lymphocyt
interstiti
lung
diseas
ild
develop
genet
analysi
reveal
compound
heterozyg
mutat
affect
lrba
initi
abatacept
therapi
mgkg
everi
week
allevi
lymphoprolifer
diarrhea
persist
die
due
persist
thrombocytopenia
subsequ
intracrani
hemorrhag
patient
previous
describ
femal
patient
success
transplant
match
sibl
donor
unknown
mutat
statu
follow
condit
regimen
busulfan
mgkg
fludarabin
atg
mgkg
patient
current
male
patient
born
consanguin
parent
present
age
year
therapyresist
itp
lymphoprolifer
sever
chronic
diarrhea
complet
blood
count
normal
immunoglobulin
within
refer
rang
age
furthermor
immun
cell
subclass
analysi
includ
b
cell
subset
lymphocyt
activ
respons
normal
genet
investig
reveal
stopgain
mutat
lrba
hsct
perform
match
sibl
donor
heterozyg
mutat
nonmyeloabl
condit
busulfan
mgkg
fludarabin
antithymocyt
globulin
atg
mgkg
administ
total
stem
cell
infus
neutrophil
thrombocyt
engraft
occur
day
respect
day
posttransplant
cmv
infect
result
episod
therapyresist
itp
led
chronic
hemorrhag
due
complic
cathet
insert
weekli
administr
romiplostim
increas
thrombocyt
count
within
week
posttranspl
day
patient
episod
autoimmun
hemolyt
anemia
resist
ivig
replac
therapi
methylprednisolon
mgkg
introduc
sirolimu
initi
due
second
attack
autoimmun
hemolysi
control
steroid
dose
rapidli
taper
current
sirolimu
therapi
posttranspl
year
mixeddonor
chimer
lrba
protein
express
test
month
transplant
found
reduc
compar
healthi
control
howev
express
similar
lrba
express
heterozyg
match
sibl
donor
fig
patient
elder
sister
patient
diagnost
workup
brother
dna
sampl
also
studi
stop
codon
mutat
detect
although
complet
asymptomat
gener
immun
workup
normal
slightli
low
switchedmemori
b
cell
neg
autoantibodi
ana
asma
anca
antitpo
antithyroglobulin
tissu
transglutaminas
antibodi
well
direct
coomb
test
abdomin
ultrasound
normal
deep
lymphadenopathi
detect
vaccin
respons
normal
despit
find
lrba
express
pbmc
assess
immunofluoresc
stain
absent
fig
concord
identifi
mutat
patient
current
followup
patient
male
present
autoimmun
hemolyt
anemia
itp
hepatosplenomegali
unexplain
urticaria
angioedema
episod
year
old
past
medic
histori
unremark
recurr
infect
initi
laboratori
investig
demonstr
pancytopenia
serum
immunoglobulin
peripher
blood
lymphocyt
subset
within
normal
rang
doubleneg
cell
total
lymphocyt
patient
initi
diagnos
autoimmun
lymphoprolif
syndrom
receiv
steroid
mycophenol
mofetil
mmf
immunosuppress
treatment
followup
serum
immunoglobulin
decreas
gradual
ivig
replac
start
splenectomi
perform
due
steroiddepend
pancytopenia
hypersplen
cytopenia
allevi
follow
splenectomi
normal
neutrophil
thrombocyt
count
achiev
howev
month
later
develop
tachypnea
left
axillari
lymphadenopathi
ct
scan
reveal
nodular
opac
lymphocyt
interstiti
lung
diseas
lymph
node
biopsi
show
reactiv
lymphocytosi
genet
investig
identifi
compound
heterozyg
mutat
lrba
c
result
absent
protein
express
fig
b
abatacept
introduc
mgkg
everi
week
pulmonari
lesion
resolv
markedli
fig
match
unrel
donor
survey
activ
plan
allogen
hsct
heredescrib
patient
lrba
mutat
either
homozyg
compound
heterozyg
mutat
cohort
group
consist
five
differ
famili
three
consanguin
three
seven
patient
deceas
time
analysi
two
live
patient
underw
hsct
averag
age
diseas
onset
sd
year
interestingli
cohort
includ
asymptomat
lrba
mutant
patient
common
clinic
manifest
six
symptomat
patient
organomegali
autoimmun
chronic
diarrhea
tabl
splenomegali
hepatomegali
could
observ
cohort
five
patient
present
organomegali
togeth
lymphadenopathi
lymph
node
biopsi
three
patient
show
reactiv
lymphocytosi
progress
lymphoma
seen
cohort
autoimmun
mainli
present
immunemedi
cytopenia
five
patient
recurr
itp
episod
ivig
steroid
use
tabl
one
patient
resist
itp
occasion
respond
plasma
exchang
therapi
die
intracrani
hemorrhag
itp
episod
abatacept
therapi
aiha
observ
three
patient
one
patient
splenectom
control
therapyresist
cytopenia
success
term
recoveri
cytopenia
two
present
patient
earlyonset
diabet
one
patient
autoimmun
thyroid
one
patient
chronic
urticaria
autoimmun
manifest
diarrhea
protract
resist
immunosuppress
agent
steroid
mmf
cyclosporin
csa
specif
infecti
pathogen
could
isol
therapyresist
diarrhea
caus
malnutrit
growth
failur
three
patient
led
us
administ
tpn
calor
compens
colonoscop
examin
patient
diarrhea
reveal
ibdlik
mucos
pattern
intraepitheli
lymphocytosi
similar
celiac
diseas
observ
duoden
biopsi
patient
least
one
document
infecti
episod
followup
recurr
respiratori
tract
infect
timesyear
result
hospit
present
three
patient
initi
present
viral
pathogen
common
infecti
agent
coronaviru
frequent
virus
includ
cmv
rsv
adenoviru
detect
patient
regardless
therapeut
scheme
sever
bacteri
infect
caus
acinetobact
baumanii
staphylococcu
aureu
document
two
patient
immunosuppress
therapi
methylprednisolon
cyclosporin
tabl
candida
glabrata
candida
krusei
also
isol
two
patient
parasit
infect
document
addit
abovement
autoimmunemedi
cytopenia
itp
aiha
two
patient
lymphopen
initi
admiss
neutropenia
observ
patient
despit
normal
cell
count
patient
two
present
reduc
activ
respons
phytohemagglutinin
stimul
tabl
howev
patient
chronic
immunosuppress
therapi
analysi
perform
doubleneg
cell
dnt
elev
four
patient
tabl
previous
diagnos
alp
total
b
cell
number
alter
one
patient
howev
patient
immunosuppres
treatment
time
analysi
tabl
b
cell
subpopul
analysi
reveal
low
number
switchedmemori
b
cell
number
two
four
test
patient
none
patient
hypogammaglobulinemia
admiss
yet
one
patient
develop
followup
combin
low
switchedmemori
b
cell
homozyg
mutat
identifi
four
patient
compound
heterozyg
mutat
three
heredescrib
mutat
segreg
perfectli
diseas
parent
compound
heterozyg
patient
carri
one
two
variant
parent
homozyg
patient
heterozyg
mutat
one
except
asymptomat
patient
show
sign
immun
dysregul
carrier
homozyg
nonsens
mutat
heredescrib
mutat
describ
fig
novel
well
known
mutat
distribut
along
whole
protein
length
specif
genotypephenotyp
correl
observ
protein
express
analysi
perform
cell
deriv
patient
reveal
complet
absenc
lrba
well
materi
deriv
patient
transplant
fig
patient
transplant
heterozyg
match
sibl
donor
hmsd
individu
show
reduc
lrba
express
comparison
healthi
control
fig
absenc
lrba
protein
patient
confirm
immunofluoresc
analysi
patientderiv
peripher
blood
mononuclear
cell
stimul
antibodi
fig
concord
genet
data
analysi
asymptomat
sibl
also
reveal
absent
lrba
fig
patient
present
sever
immun
dysregul
three
patient
die
diseas
cours
two
patient
underw
hsct
match
sibl
donor
reducedintens
condit
regim
consist
fludarabin
atg
mgkg
busulfan
mgkg
use
tabl
previous
publish
patient
unev
posttranspl
followup
current
month
hsct
diarrhea
autoimmun
episod
patient
also
unev
period
initi
encount
itp
aiha
episod
follow
hsct
current
year
hsct
sirolimu
romiplostim
mixeddonor
chimer
patient
also
plan
hsct
survey
match
unrel
donor
still
continu
although
present
patient
cohort
cur
treatment
transplant
patient
receiv
multipl
immunosuppress
treatment
patient
receiv
chronic
intermitt
steroid
symptom
unrespons
steroidspar
agent
previous
mmf
use
two
patient
csa
use
one
patient
use
abatacept
two
patient
protocol
mgkg
everi
week
patient
five
dose
abatacept
treatment
itp
persist
fatal
outcom
lymphoprolifer
allevi
patient
current
abatacept
therapi
lymphocyt
interstiti
pneumonia
lymphocyt
infiltr
lung
resolv
third
dose
fig
current
studi
present
singlecent
experi
lrba
defici
seven
affect
individu
five
famili
today
patient
lrba
defici
report
number
keep
increas
although
diseas
classifi
cvidlik
disord
recent
report
extend
diseas
phenotyp
reveal
promin
clinic
featur
lrba
defici
due
immun
dysregul
present
mostli
enteropathi
autoimmun
hemolyt
anemia
itp
concord
organomegali
enteropathi
autoimmun
cytopenia
common
featur
cohort
patient
present
alpslik
phenotyp
organomegali
lymphoprolifer
elev
dnt
followup
alp
diagnosi
genet
analysi
previous
lrbadefici
patient
report
suffer
alpslik
phenotyp
recommend
lrba
defect
consid
patient
neg
mutat
alp
gene
fa
fasl
present
patient
cohort
first
analysi
group
turkish
patient
lrba
mutat
previous
two
report
separ
group
although
includ
overlap
case
review
phenotyp
manifest
patient
bear
lrba
mutat
major
phenotyp
group
categori
autoimmun
enteropathi
cvidlik
immun
defici
although
patient
present
characterist
autoimmun
enteropathi
phenotyp
cvidlik
immun
defici
frequent
cohort
tabl
studi
patient
group
hypogammaglobulinemia
promin
diseas
featur
alpslik
diseas
without
diarrhea
common
initi
present
could
illustr
specif
genotypephenotyp
relationship
phenomenon
observ
cohort
chronic
diarrhea
troublesom
diseas
symptom
present
patient
caus
prolong
hospit
tpn
administr
calor
compens
diarrhea
usual
initi
symptom
develop
diseas
cours
pathogen
could
identifi
underli
caus
furthermor
diarrhea
unrespons
standard
immunosuppress
therapi
steroid
mmf
colonoscop
evalu
reveal
ibdlik
mucos
inflamm
intraepitheli
lymphocyt
infiltr
duodenum
celiaclik
pattern
common
histopatholog
find
howev
none
patient
respond
glutenfre
diet
concord
previous
publish
data
describ
patient
cohort
diarrhea
could
control
hsct
record
sever
diseas
cours
averag
age
onset
year
slightli
younger
report
previou
studi
howev
one
patient
neg
lrba
protein
express
fig
carri
stop
codon
mutat
diseas
brother
asymptomat
age
year
current
immun
workup
normal
apart
slightli
reduc
number
switchedmemori
b
cell
autoimmun
diseas
document
asymptomat
patient
describ
previous
howev
diseas
onset
vari
patient
latest
age
onset
far
year
asymptomat
individu
cohort
current
close
followup
without
treatment
diseas
cours
patient
sever
often
fatal
without
appropri
intervent
three
seven
patient
die
result
enteropathi
complic
immunosuppress
treatment
lrba
patient
need
earli
interdisciplinari
care
howev
due
lack
genotypephenotyp
correl
clinic
heterogen
diseas
present
standard
therapeut
approach
patient
yet
recent
abatacept
protein
introduc
promis
agent
improv
clinic
symptom
lrbadefici
patient
howev
far
longterm
effect
safeti
costeffect
therapi
analyz
use
abatacept
treatment
two
patient
patient
appli
abatacept
ild
respond
well
three
dose
lymphocyt
infiltr
disappear
respiratori
function
improv
patient
receiv
abatacept
treat
resist
thrombocytopenia
lymphoprolifer
enteropathi
although
lymphoprolifer
allevi
diarrhea
persist
thrombocytopenia
deterior
result
death
patient
due
intracrani
hemorrhag
increas
evid
persist
abatacept
infus
correct
autoimmun
phenotyp
lrba
patient
howev
symptom
respons
five
patient
report
receiv
abatacept
three
case
major
complaint
respiratori
dysfunct
result
lung
infiltr
respond
complet
abatacept
accord
experi
patient
lymphoprolif
symptom
allevi
wherea
enteropathi
cytopenia
persist
follow
abatacept
date
give
clear
advic
whether
treat
abatacept
data
need
precis
therapeut
indic
effect
abatacept
therapi
given
sever
complic
observ
patient
includ
high
mortal
rate
hsct
might
promis
strategi
prefer
hsct
reducedintens
condit
regimen
consist
fludarabin
atg
busulfan
target
areaundertheconcentr
versu
time
curv
auc
busulfan
dose
aim
publish
protocol
chronic
granulomat
diseas
two
patient
underw
hsct
use
reducedintens
condit
respond
well
diarrhea
major
problem
patient
ceas
day
follow
stem
cell
infus
first
lrbadefici
patient
underw
hsct
regim
current
posttranspl
year
unev
survey
second
patient
one
itp
autoimmun
hemolyt
anemia
episod
first
year
post
hsct
could
control
administr
romiplostim
sirolimu
respect
present
patient
cumul
burden
chronic
inflamm
combin
organ
damag
reducedintens
condit
option
hsct
lrbadefici
patient
report
treat
hsct
overal
surviv
note
patient
complet
good
partial
remiss
howev
posttranspl
autoimmun
manifest
infrequ
lrba
patient
specul
autoimmun
manifest
seen
patient
may
relat
donor
heterozyg
carrier
diseas
allel
today
control
studi
whether
hsct
abatacept
prefer
treatment
option
lrba
defici
given
chronic
requir
replac
abatacept
treatment
might
bridg
strategi
hsct
autosom
recess
disord
rel
common
turkey
due
high
frequenc
consanguin
marriag
lrba
defect
alway
kept
mind
differenti
diagnosi
patient
autoimmun
diseas
affect
multipl
organ
chronic
diarrhea
organomegali
experi
earli
hsct
lifesav
therapeut
strategi
